PMC9947835_01
Representative Hematoxylin & Eosin Slide of Outside Referral Biopsy from Patient 1. Sample collected in February 2020, pre-treatment, image is at 10X magnification.
fonc-13-1046442-g001.jpg
PMC9947835_01_fonc-13-1046442-g001.jpg
f1
Pathologic evaluation of the uterine mass revealed a large (>15cm) high-grade myxoid pleomorphic spindle and epithelioid sarcoma (  Figure 1  ), positive metastatic lymph nodes, and tumor present at the resection margins.
Timeline of Treatments of Patient 1. Treatment lines are displayed chronologically, with imaging assessments at baseline, at time of best response to treatment, and at time of end of treatment for each line of treatment. Initial pathology diagnostic and molecular profiles are displayed. IHC, immunohistochemistry; LOF, loss-of-function; MSI, microsatellite instable; PD, Progressive Disease; PR, Partial Response; TMB, tumor mutational burden; VAF, variant allele fraction.
fonc-13-1046442-g002.jpg
PMC9947835_01_fonc-13-1046442-g002.jpg
f2
Her performance status remains better than 8 months ago, before starting treatment ( Figure 2 ).
PMC9947835_02
Representative Hematoxylin & Eosin Slide of Outside Referral Biopsy from Patient 2 Samples collected in December 2020 (A), January 2021 (B), and March 2021 (C), all pre-treatment, image is at 10X magnification.
fonc-13-1046442-g003.jpg
PMC9947835_02_fonc-13-1046442-g003.jpg
f3
A hematoma was suspected and thus, she underwent incomplete resection revealing a 5.5cm high-grade myxofibrosarcoma of the thigh with 23 mitosis in 10 high power field and 20% necrosis on December 4th, 2020 (  Figure 3  ).
Timeline of Treatments of Patient 2. Treatment lines are displayed chronologically, with imaging assessments at baseline, at time of best response to treatment, and at time of end of treatment for each line of treatment. Initial pathology diagnostic and molecular profiles are displayed. HPF, high power field; IHC, immunohistochemistry; LOF, loss-of-function; MSI, microsatellite instable; PD, Progressive Disease; PR, Partial Response; SD, Stable Disease; TMB, tumor mutational burden; VAF, variant allele fraction.
fonc-13-1046442-g004.jpg
PMC9947835_02_fonc-13-1046442-g004.jpg
f4
Toxicities noted on-treatment include grade 3 neutropenia and anemia, grade 2 fatigue, and grade 1 pelvic pain residual from radiation treatment (  Figure 4  ).